EXPERIMENTED LONG-ACTING INJECTABLE ANTIRETROVIRAL THERAPY AND LINK WITH AMBULATORY MEDICINE AMONG ADULT PEOPLE LIVING WITH HIV: THE REAL-LIFE PANTER STUDY
Author(s)
Tristan Alain, MS1, christia palacios, MD2, Axel UrsenBach, MD3, Fabienne Marcellin, MS4, Saleh Fahmi, MS5, Carole Abeguille, MS5, Jade Ghosn, PhD, MD6, Abi Aad Yasmine, MD7, hocqueloux laurent, MD8, Clotilde Allavena, MD9, David Zucman, MD10, Martin Duracinsky, PhD, MD11.
1Assistance Publique Hopitaux de Paris URCEco, Paris, France, 2Infectious diseases service, AP-HP, Tenon hospital,, Paris, France, 3Le Trait d’Union, HIV-Infection Care Center, Strasbourg University Hospital,, Strasbourg, France, 4Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France, 5Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Center (URC-ECO), Hôtel-Dieu Hospital,, Paris, France, 6Virology department, Université Paris Cité, INSERM, UMR1137, IAME, Bichat-Claude Bernard hospital, AP-HP – Infectious diseases department, AP-HP, Bichat-Claude-Bernard hospital, Paris, France, 7Infectious Diseases department, Saint-Antoine hospital, AP-HP, Paris, France!, Paris, France, 8University Hospital Center, Orléans, Orléans, France, 98INSERM CIC 1413, Infectious Diseases Department, CHU Nantes, Nantes, France, 10Foch Hospital, Department of internal medicine, Suresnes, France, 11Patient-Centered Outcomes Research (PROQOL), Paris, France.
1Assistance Publique Hopitaux de Paris URCEco, Paris, France, 2Infectious diseases service, AP-HP, Tenon hospital,, Paris, France, 3Le Trait d’Union, HIV-Infection Care Center, Strasbourg University Hospital,, Strasbourg, France, 4Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France, 5Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Center (URC-ECO), Hôtel-Dieu Hospital,, Paris, France, 6Virology department, Université Paris Cité, INSERM, UMR1137, IAME, Bichat-Claude Bernard hospital, AP-HP – Infectious diseases department, AP-HP, Bichat-Claude-Bernard hospital, Paris, France, 7Infectious Diseases department, Saint-Antoine hospital, AP-HP, Paris, France!, Paris, France, 8University Hospital Center, Orléans, Orléans, France, 98INSERM CIC 1413, Infectious Diseases Department, CHU Nantes, Nantes, France, 10Foch Hospital, Department of internal medicine, Suresnes, France, 11Patient-Centered Outcomes Research (PROQOL), Paris, France.
OBJECTIVES: Long-acting (LA) injectable antiretroviral therapy (ART) represents a potentially significant shift in treatment experience and disease management for people living with HIV (PLWH). However, it is also associated with challenges in the organization of care pathways, with the need to increase the role of primary care in treatment delivery and follow-up of PLWH after switch. We analyzed adult PLWH’s experience of switching to LA-ART with cabotegravir/rilpivirine (LA-CAB/RPV) 3 and 9 months after switch.
METHODS: The PANTER observational real life, multicenter study assesses patient-reported outcomes in PLWH followed-up in French hospitals and switching from oral ART to LA-CAB/RPV. We described PLWH’s characteristics, the first experience with LA-CAB/RPV 3 months after, and the preferences for hospital or outpatient care 9 months after switch.
RESULTS: From August 2023 to May 2025, 300 PLWH (male 66%, mean (SD) age: 44 (12) years) were included in 22 centers. At enrolment, mean ART duration was 12 (9) years, 46% of PLWH had at least one comorbidity, and 96% on daily ART. At month 3 (n=263), 97% of PLWH preferred LA-CAB/RPV to oral ART. The main reported reasons were greater treatment convenience (77%), not having to carry the treatment (75%), a more convenient administration frequency (64%), and spending less time keeping track of treatment (44%). At month 9 (n=261), 56% reported having received the last injections at hospital, 33% in outpatient care facilities, and 11% at home. Forty-one percent of PLWH reported difficulties finding a community nurse, while 33% of those obtaining their treatment from a community pharmacy reported that the treatment not held in stock and had to be ordered.
CONCLUSIONS: The high acceptability of LA-CAB/RPV among PLWH is accompanied by logistical challenges that should be addressed to facilitate its implementation in community settings. Strengthening coordination between pharmacies, community nurses, and hospitals could help improve continuity of care.
METHODS: The PANTER observational real life, multicenter study assesses patient-reported outcomes in PLWH followed-up in French hospitals and switching from oral ART to LA-CAB/RPV. We described PLWH’s characteristics, the first experience with LA-CAB/RPV 3 months after, and the preferences for hospital or outpatient care 9 months after switch.
RESULTS: From August 2023 to May 2025, 300 PLWH (male 66%, mean (SD) age: 44 (12) years) were included in 22 centers. At enrolment, mean ART duration was 12 (9) years, 46% of PLWH had at least one comorbidity, and 96% on daily ART. At month 3 (n=263), 97% of PLWH preferred LA-CAB/RPV to oral ART. The main reported reasons were greater treatment convenience (77%), not having to carry the treatment (75%), a more convenient administration frequency (64%), and spending less time keeping track of treatment (44%). At month 9 (n=261), 56% reported having received the last injections at hospital, 33% in outpatient care facilities, and 11% at home. Forty-one percent of PLWH reported difficulties finding a community nurse, while 33% of those obtaining their treatment from a community pharmacy reported that the treatment not held in stock and had to be ordered.
CONCLUSIONS: The high acceptability of LA-CAB/RPV among PLWH is accompanied by logistical challenges that should be addressed to facilitate its implementation in community settings. Strengthening coordination between pharmacies, community nurses, and hospitals could help improve continuity of care.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR167
Topic
Health Service Delivery & Process of Care, Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Infectious Disease (non-vaccine)